Search Results - "Retel, VP"

A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study by Drukker, C.A., Bueno‐de‐Mesquita, J.M., Retèl, V.P., Harten, W.H., Tinteren, H., Wesseling, J., Roumen, R.M.H., Knauer, M., Veer, L.J., Sonke, G.S., Rutgers, E.J.T., Vijver, M.J., Linn, S.C.

“…The 70‐gene signature (MammaPrint™) has been developed on retrospective series of breast cancer patients to predict the risk of breast cancer distant…”
Get full text

EffectiveNess of a multimodal preHAbilitation program in patieNts with bladder canCEr undergoing radical cystectomy: protocol of the ENHANCE multicentre randomised controlled trial by Akdemir, Emine, Sweegers, Maike G, Vrieling, Alina, Rundqvist, Helene, Meijer, Richard P, Leliveld-Kors, Annemarie M, van der Heijden, Antoine G, Rutten, Vera C, Koldewijn, Evert L, Bos, Siebe D, Wijburg, Carl J, Marcelissen, Tom A T, Bongers, Bart C, Retèl, Valesca P, van Harten, Wim H, May, Anne M, Groen, Wim G, Stuiver, Martijn M

“…IntroductionRadical cystectomy (RC) is the standard treatment for patients with non-metastatic muscle-invasive bladder cancer, as well as for patients with…”
Get full text

Abstract OT2-07-08: Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO) - an international randomized phase III trial by Vliek, S, Jager, A, Jonge-Lavrencic, M, Lotz, J-P, Gonçalves, A, Graeser, M, Nitz, U, Mandjes, IAM, Holtkamp, MJ, Schot, M, Retel, VP, Kuip, EJ, Wymenga, MN, Konings, IR, Tjan-Heijnen, VCG, Kroep, JR, Schroeder, CP, Van der Wall, E, Linn, SC

“…Abstract Background: An intact homologous repair (HR) pathway is essential for error-free repair of DNA double strand breaks (DSB). Preclinical and clinical…”
Get full text

Abstract P6-06-13: Optimized prediction of clinical outcome by the PREDICT plus tool and the 70-gene signature in early stage node-negative breast cancer by Drukker, CA, Nijenhuis, MV, Bueno-de-Mesquita, JM, Retel, VP, van Tinteren, H, Schmidt, MK, van Harten, WH, Sonke, GS, van 't Veer, LJ, Rutgers, EJ, van de Vijver, MJ, Linn, SC

“…Abstract Background Established breast cancer guidelines and online tools use clinico-pathological factors including age, tumor size and grade to evaluate the…”
Get full text

Abstract P5-15-08: Economic Impact of MammaPrint (70-gene signature) in a clinical high risk population: A 10yr Markov model, 6,000-patient retrospective analysis of US claim data by Blumencranz, LE, Høst-Ragab, A, Retèl, VP, Garlich, H, Hwang, C, Neijenhuis, S, Habibi, M, Audeh, W

“…Abstract Background: MINDACT provided evidence that MammaPrint (MP) can identify patients (pts) with early-stage breast cancer (ESBC) who can safely forego…”
Get full text

Barriers and facilitators of patient access to medical devices in Europe: A systematic literature review by Beck, ACC, Retèl, VP, Bhairosing, PA, van den Brekel, MWM, van Harten, WH

“…•Across Europe, market access is uniform, whereas reimbursement procedures are heterogeneous.•Time to access is mainly influenced by reimbursement…”
Get full text

Abstract P4-12-01: MammaPrint is cost-effective compared to clinical risk assessment in early stage breast cancer by Retèl, VP, Joore, MA, van 't Veer, LJ, Cardoso, F, Piccart, MJ, Rutgers, EJ, Tryfonidis, K, Poncet, C, van Harten, WH

“…Abstract Rationale: The 70-gene signature (MammaPrint®, MP) is a prognostic test which guides treatment decisions in patients with early breast cancer. After…”
Get full text

A Health Technology Assessment of Hyperthermic Intraperitoneal Chemotherapy Added to Interval Cytoreductive Surgery in Stage III Ovarian Cancer by Retèl, VP, van Lieshout, C, Koole, S, Sikorska, K, Sonke, GS, van Driel, WJ, van Harten, WH

“…OBJECTIVES: Hyperthermic intraperitoneal chemotherapy (HIPEC) is a new addition to standard treatment of stage III ovarian cancer with neoadjuvant chemotherapy…”
Get full text

PCN121 - A Health Technology Assessment of Hyperthermic Intraperitoneal Chemotherapy Added to Interval Cytoreductive Surgery in Stage III Ovarian Cancer by Retèl, VP, van Lieshout, C, Koole, S, Sikorska, K, Sonke, GS, van Driel, WJ, van Harten, WH

Get full text

Innovations that reach the patient: early health technology assessment and improving the chances of coverage and implementation by van Harten, W H, Retèl, V P

“…With growing concerns for the sustainability of the financial burden that health care-and especially cancer services-poses on the national budgets, the role of…”
Get full text

Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology by van Harten, W H, Retèl, V P

“…The Organisation of European Cancer Institutes OECI working group on Health Economics and Cost Benefit in Oncology suggests four actions that are needed to…”
Get full text